Developer docs
API playgroundTry for free, no card

Search company profiles

Aiosyn

Full company profile

uuid0000fam

Namestring
Aiosyn
Legal namestring
Aiosyn
Websiteurl
aiosyn.org
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Aiosyn is a Dutch medical-software company developing CE-IVDR certified AI algorithms for pathology diagnostics, founded in 2021 and headquartered in Nijmegen, Netherlands. The company builds deep learning computer vision models that analyze histopathology images to automate diagnostic tasks in oncology and nephrology, with a technology base rooted in more than 20 years of academic research at Radboud University Medical Center (Radboudumc).

Aiosyn's product portfolio centers on three solutions: Aiosyn Mitosis Breast, the world's first CE-IVDR certified AI for automated mitosis detection in breast cancer diagnostics, claimed to deliver 60% faster analysis and 32.6% improved consistency versus standard methods; AiosynQC, a pre-scan quality control module that identifies eight or more artifact types before slide imaging; and the NephroPath Platform, an edge-AI research tool capable of analyzing fifteen or more kidney structures for kidney pathology research. The technology is delivered as enterprise software to hospital and independent pathology laboratories, with the flagship product positioned as plug-and-play compatible with existing digital pathology workflows.

Commercially, Aiosyn operates a sales-led, direct enterprise motion targeting pathology labs across Europe through demo-request funnels on aiosyn.org and direct outreach, monetizing through recurring software licensing agreements. The company is privately held and venture-backed, having raised approximately $6.4M cumulatively across a 2022 seed round led by Health Innovations (with LUMO Labs and OostNL), a 2023 EFRO-OOST grant under the AIRAT project with Radboudumc and Pathologie-DNA, and a 2025 round that added TNO Ventures. A 2026 strategic partnership with TNO extends the roadmap into functional and digital biomarker development, while the 2025 spin-off of AIKON Health explores an adjacent cardiac-monitoring vertical.

Short descriptiontext

Aiosyn is a Nijmegen-based medical-software company that develops CE-IVDR certified deep learning AI for pathology diagnostics, selling enterprise software to European pathology laboratories for breast cancer mitosis detection, pre-scan quality control, and kidney pathology research.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNijmegen, Netherlands
HQ citystring
Nijmegen
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI pathology diagnostics, medical imaging software, computational pathology, cancer diagnostics AI, digital pathology solutions
Industry4 codes
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACAMAB
Anatomic Pathology LIS & Digital Pathology Workflow
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics
NAICS code2 codes
  • Software Publishers5132
  • Software Publishers513210
SIC code2 codes
  • Services-Prepackaged Software7372
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
AI Pathology Diagnostics Software
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1AI Pathology Software Licensing
TypeSubscription Recurring
Description

Sale of CE-IVDR certified AI pathology diagnostic software to pathology labs and medical institutions across Europe. Revenue generated through software licensing agreements with healthcare facilities.

aiosyn.org
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1Aiosyn Mitosis Breast
Description

World's first certified AI for mitosis detection in breast cancer diagnostics

aiosyn.org
+2 more records
Core offering1 text field

Aiosyn develops and sells CE-IVDR certified AI-powered medical software for pathology diagnostics, focusing on automated mitosis detection in breast cancer, pre-scan quality control of pathology slides, and edge AI analysis for kidney pathology research. The software is sold under a SaaS/subscription licensing model to hospital and independent pathology laboratories across Europe, integrating directly into existing digital pathology workflows.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 60% faster cancer detection with Aiosyn Mitosis Breast
+3 more records
Product overview1 text field

Aiosyn offers three CE-IVDR certified AI-powered pathology diagnostic products. Aiosyn Mitosis Breast is the flagship product—the world's first certified AI for automated mitosis detection in breast cancer diagnostics. AiosynQC provides automated pre-scan quality control for artifact detection across 8+ artifact types. The NephroPath Platform delivers edge AI capabilities for advanced kidney pathology research, detecting 15+ kidney structures. Together, these products form a comprehensive AI pathology suite addressing cancer diagnostics, quality assurance, and kidney disease research across European pathology labs.

Product and service3 records
1Aiosyn Mitosis Breast
CategoryAI Pathology Diagnostics Software
Description

World's first CE-IVDR certified AI solution for automated mitosis detection in breast cancer diagnostics, achieving 60% faster analysis and +32.6% improved consistency versus standard methods. Designed for pathology laboratories running digital pathology workflows for breast cancer diagnosis.

2AiosynQC
CategoryAI Pathology Quality Control Software
Description

Automated pre-scan quality control software that detects 8+ artifact types before imaging to ensure pathology slide image quality and prevent downstream rework. Built for digital pathology laboratories.

3NephroPath Platform
CategoryAI Kidney Pathology Research Platform
Description

Edge AI platform for advanced kidney pathology research capable of detecting 15+ kidney structures using on-device edge AI processing. Targeted at academic medical centers and research institutions conducting computational nephropathology and biomarker research.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierFlagshipTypeTechnology or IntegrationAnnounced on2026-05-13
Description

Strategic technology partnership focused on biomarker innovation for healthcare. TNO, a Dutch independent research organization, partnered with Aiosyn to accelerate development of functional and digital biomarkers. The partnership aims to improve healthcare quality, affordability, and accessibility through AI-driven precision pathology solutions.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-05-09
Description

Long-term academic research partnership spanning 20+ years. Radboudumc provides the academic foundation for Aiosyn's AI pathology technology development. The partnership includes joint development of AI-enabled tools for cancer diagnosis under the AIRAT project, with €1.3 million EFRO grant funding.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-05-09
Description

Collaborative partnership under the AIRAT project to develop AI technology for breast and skin cancer diagnostics. Pathologie-DNA contributes pathology expertise alongside Radboudumc and Aiosyn. The project received €1.3 million EFRO-OOST grant funding for development of CE-marked deep learning algorithms for automated mitosis detection.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Israel-based AI pathology company offering CE-IVD-certified clinical decision-support tools for cancer diagnosis across multiple tissue types. Directly comparable to Aiosyn in product category, regulatory positioning, and target customer (pathology labs).

TypeDirect peer
Description

US-based AI pathology company with FDA-authorized products for prostate and breast cancer detection. Comparable to Aiosyn in computer-vision-on-histopathology focus, though operating at significantly larger scale and capital base.

TypeDirect peer
Description

US-based AI pathology platform serving biopharma, diagnostics, and clinical customers with deep-learning tissue analysis. Comparable in technology stack (deep learning on histopathology) and enterprise go-to-market, though much broader in scope.

TypeDirect peer
Description

France-based AI biotech applying machine learning to pathology and clinical research, including federated learning approaches. Comparable in applying AI to histopathology for oncology, with a stronger biopharma-services angle.

TypeDirect peer
Description

Hamburg-based AI pathology company offering CE-IVD-marked image-analysis tools for breast and other cancer diagnostics. Closely comparable European peer in product, regulatory positioning, and target pathology-lab customer base.

6Aignostics
TypeDirect peer
Description

Berlin-based AI pathology company spun out from Charité, developing computational pathology models for oncology and biomarker discovery. Comparable in academic origin, European footprint, and AI-on-histopathology focus.

TypeDirect peer
Description

US-based digital pathology platform combining slide management software with AI applications for cancer diagnosis. Comparable in pathology AI focus, though offers a broader enterprise platform versus Aiosyn's point-solution suite.

TypeBroad incumbent
Description

AI-powered radiology and pathology imaging subsidiary of RadNet, offering FDA-cleared diagnostic algorithms. Comparable as an AI-imaging-diagnostics vendor, though operating in a broader radiology-plus-pathology portfolio with much greater scale.

TypeBroad incumbent
Description

Global diagnostics incumbent offering the uPath digital pathology platform and integrated AI partnerships. Comparable as a digital pathology infrastructure provider; though much larger and broader, with potential to acquire or compete against point AI vendors like Aiosyn.

TypeRegional player
Description

Austria-based provider of automated tissue analysis and digital pathology solutions for research and clinical use. Comparable in European pathology AI focus, though with a stronger research-tooling orientation rather than diagnostic SaMD.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aiosyn

AI Pathology Diagnostics Softwareaiosyn.org

Aiosyn is a Nijmegen-based medical-software company that develops CE-IVDR certified deep learning AI for pathology diagnostics, selling enterprise software to European pathology laboratories for breast cancer mitosis detection, pre-scan quality control, and kidney pathology research.

What Aiosyn does

Aiosyn is a Dutch medical-software company developing CE-IVDR certified AI algorithms for pathology diagnostics, founded in 2021 and headquartered in Nijmegen, Netherlands. The company builds deep learning computer vision models that analyze histopathology images to automate diagnostic tasks in oncology and nephrology, with a technology base rooted in more than 20 years of academic research at Radboud University Medical Center (Radboudumc).

Aiosyn's product portfolio centers on three solutions: Aiosyn Mitosis Breast, the world's first CE-IVDR certified AI for automated mitosis detection in breast cancer diagnostics, claimed to deliver 60% faster analysis and 32.6% improved consistency versus standard methods; AiosynQC, a pre-scan quality control module that identifies eight or more artifact types before slide imaging; and the NephroPath Platform, an edge-AI research tool capable of analyzing fifteen or more kidney structures for kidney pathology research. The technology is delivered as enterprise software to hospital and independent pathology laboratories, with the flagship product positioned as plug-and-play compatible with existing digital pathology workflows.

Commercially, Aiosyn operates a sales-led, direct enterprise motion targeting pathology labs across Europe through demo-request funnels on aiosyn.org and direct outreach, monetizing through recurring software licensing agreements. The company is privately held and venture-backed, having raised approximately $6.4M cumulatively across a 2022 seed round led by Health Innovations (with LUMO Labs and OostNL), a 2023 EFRO-OOST grant under the AIRAT project with Radboudumc and Pathologie-DNA, and a 2025 round that added TNO Ventures. A 2026 strategic partnership with TNO extends the roadmap into functional and digital biomarker development, while the 2025 spin-off of AIKON Health explores an adjacent cardiac-monitoring vertical.

Aiosyn firmographics

Firmographics
Name
Aiosyn
Legal name
Aiosyn
Website
https://aiosyn.org
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Short description
Aiosyn is a Nijmegen-based medical-software company that develops CE-IVDR certified deep learning AI for pathology diagnostics, selling enterprise software to European pathology laboratories for breast cancer mitosis detection, pre-scan quality control, and kidney pathology research.
Ownership category
akta.pro rank

Aiosyn industry classification

Industry
Product category
AI Pathology Diagnostics Software
NAICS
Software Publishers (5132), Software Publishers (513210)
SIC
Services-Prepackaged Software (7372), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACAMAB
Anatomic Pathology LIS & Digital Pathology Workflow
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics

Keywords

  • AI pathology diagnostics
  • Medical imaging software
  • Computational pathology
  • Cancer diagnostics AI
  • Digital pathology solutions

Where Aiosyn is headquartered

Location

Headquarters

HQ city
Nijmegen
HQ country
Netherlands
HQ region
Europe

Offices1 record

Markets served

Aiosyn business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. AI Pathology Software Licensing: Sale of CE-IVDR certified AI pathology diagnostic software to pathology labs and medical institutions across Europe. Revenue generated through software licensing agreements with healthcare facilities.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Aiosyn product offering

Product offering

Core offering

Aiosyn develops and sells CE-IVDR certified AI-powered medical software for pathology diagnostics, focusing on automated mitosis detection in breast cancer, pre-scan quality control of pathology slides, and edge AI analysis for kidney pathology research. The software is sold under a SaaS/subscription licensing model to hospital and independent pathology laboratories across Europe, integrating directly into existing digital pathology workflows.

Product overview

Aiosyn offers three CE-IVDR certified AI-powered pathology diagnostic products. Aiosyn Mitosis Breast is the flagship product—the world's first certified AI for automated mitosis detection in breast cancer diagnostics. AiosynQC provides automated pre-scan quality control for artifact detection across 8+ artifact types. The NephroPath Platform delivers edge AI capabilities for advanced kidney pathology research, detecting 15+ kidney structures. Together, these products form a comprehensive AI pathology suite addressing cancer diagnostics, quality assurance, and kidney disease research across European pathology labs.

Differentiator

Problem solved

Functional benefit

Brands

  • Aiosyn Mitosis Breast: World's first certified AI for mitosis detection in breast cancer diagnostics
  • AiosynQC
  • NephroPath Platform

Products and services

  • Aiosyn Mitosis Breast World's first CE-IVDR certified AI solution for automated mitosis detection in breast cancer diagnostics, achieving 60% faster analysis and +32.6% improved consistency versus standard methods. Designed for pathology laboratories running digital pathology workflows for breast cancer diagnosis.
  • AiosynQC Automated pre-scan quality control software that detects 8+ artifact types before imaging to ensure pathology slide image quality and prevent downstream rework. Built for digital pathology laboratories.
  • NephroPath Platform Edge AI platform for advanced kidney pathology research capable of detecting 15+ kidney structures using on-device edge AI processing. Targeted at academic medical centers and research institutions conducting computational nephropathology and biomarker research.

Quantifiable outcome

  • 60% faster cancer detection with Aiosyn Mitosis Breast
  • +3 more outcomes

Companies that use Aiosyn

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Aiosyn technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Aiosyn partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered flagship and core.

  • TNO (Netherlands Organization for Applied Scientific Research)flagshipTechnology or Integration · 13 May 2026Strategic technology partnership focused on biomarker innovation for healthcare. TNO, a Dutch independent research organization, partnered with Aiosyn to accelerate development of functional and digital biomarkers. The partnership aims to improve healthcare quality, affordability, and accessibility through AI-driven precision pathology solutions.
  • Radboud University Medical CentercoreStrategic or Co-development Partner · 9 May 2023Long-term academic research partnership spanning 20+ years. Radboudumc provides the academic foundation for Aiosyn's AI pathology technology development. The partnership includes joint development of AI-enabled tools for cancer diagnosis under the AIRAT project, with €1.3 million EFRO grant funding.
  • Pathologie-DNAcoreStrategic or Co-development Partner · 9 May 2023Collaborative partnership under the AIRAT project to develop AI technology for breast and skin cancer diagnostics. Pathologie-DNA contributes pathology expertise alongside Radboudumc and Aiosyn. The project received €1.3 million EFRO-OOST grant funding for development of CE-marked deep learning algorithms for automated mitosis detection.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Aiosyn competitors and assessment

Company assessment

Direct peers

  • Ibex Medical Analytics: Israel-based AI pathology company offering CE-IVD-certified clinical decision-support tools for cancer diagnosis across multiple tissue types. Directly comparable to Aiosyn in product category, regulatory positioning, and target customer (pathology labs).
  • Paige: US-based AI pathology company with FDA-authorized products for prostate and breast cancer detection. Comparable to Aiosyn in computer-vision-on-histopathology focus, though operating at significantly larger scale and capital base.
  • PathAI: US-based AI pathology platform serving biopharma, diagnostics, and clinical customers with deep-learning tissue analysis. Comparable in technology stack (deep learning on histopathology) and enterprise go-to-market, though much broader in scope.
  • Owkin: France-based AI biotech applying machine learning to pathology and clinical research, including federated learning approaches. Comparable in applying AI to histopathology for oncology, with a stronger biopharma-services angle.
  • Mindpeak: Hamburg-based AI pathology company offering CE-IVD-marked image-analysis tools for breast and other cancer diagnostics. Closely comparable European peer in product, regulatory positioning, and target pathology-lab customer base.
  • Aignostics: Berlin-based AI pathology company spun out from Charité, developing computational pathology models for oncology and biomarker discovery. Comparable in academic origin, European footprint, and AI-on-histopathology focus.
  • Proscia: US-based digital pathology platform combining slide management software with AI applications for cancer diagnosis. Comparable in pathology AI focus, though offers a broader enterprise platform versus Aiosyn's point-solution suite.

Broad incumbents

  • DeepHealth (RadNet): AI-powered radiology and pathology imaging subsidiary of RadNet, offering FDA-cleared diagnostic algorithms. Comparable as an AI-imaging-diagnostics vendor, though operating in a broader radiology-plus-pathology portfolio with much greater scale.
  • Roche (Digital Pathology): Global diagnostics incumbent offering the uPath digital pathology platform and integrated AI partnerships. Comparable as a digital pathology infrastructure provider; though much larger and broader, with potential to acquire or compete against point AI vendors like Aiosyn.

Regional players

  • TissueGnostics: Austria-based provider of automated tissue analysis and digital pathology solutions for research and clinical use. Comparable in European pathology AI focus, though with a stronger research-tooling orientation rather than diagnostic SaMD.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Aiosyn social profiles

Digital presence

Aiosyn compliance and trust

Trust signal

Compliance1 record

Aiosyn financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aiosyn leadership team

Management profile

Number of profiles

Profiles2 records

Aiosyn funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aiosyn M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aiosyn

What does Aiosyn do?

Aiosyn develops and sells CE-IVDR certified AI-powered medical software for pathology diagnostics, focusing on automated mitosis detection in breast cancer, pre-scan quality control of pathology slides, and edge AI analysis for kidney pathology research. The software is sold under a SaaS/subscription licensing model to hospital and independent pathology laboratories across Europe, integrating directly into existing digital pathology workflows.

Is Aiosyn a public or private company?

Aiosyn is a private company. It is classified as venture growth investor backed and is currently operating.

When was Aiosyn founded?

Aiosyn was founded in 2021. It employs 1 to 10 people.

Where is Aiosyn based?

Aiosyn is headquartered in Nijmegen, Netherlands, in the Europe region.

How does Aiosyn make money?

One revenue line is on record: AI Pathology Software Licensing.

Who are Aiosyn's main competitors?

Direct peers on record are Ibex Medical Analytics, Paige, PathAI, Owkin, Mindpeak, Aignostics and Proscia. Broad incumbents are DeepHealth (RadNet) and Roche (Digital Pathology). TissueGnostics is listed as a regional player.

Does Aiosyn have an API?

No public API is recorded for Aiosyn.

What industry is Aiosyn in?

Aiosyn's product category is AI Pathology Diagnostics Software. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays). Its NAICS code is 5132 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TnoAccelerating biomarker innovation is critical for future healthcareTNO, a Dutch independent research organization, operates as an innovator and connector in developing functional and digital biomarkers to improve healthcare quality, affordability, and accessibility. TNO recently entered a strategic technology partnership with Aiosyn, an AI-driven precision pathology startup focused on cancer diagnostics, and its spin-off AIKON Health has developed a smart patch for continuous cardiac monitoring using AI-driven algorithms. The article argues that while digital and functional biomarkers offer significant potential for early disease detection and continuous health monitoring, significant challenges remain in translating these technologies into stable, low-threshold solutions for widespread clinical use.AiosynDutch Aiosyn secures 2.4M funding to scale AI-powered cancer diagnosticsAiosyn, a Dutch AI pathology company, closed a €2.4 million funding round with investors including TNO Ventures and LUMO Labs. The funds and a new TNO partnership will accelerate its AI-driven cancer diagnostic tools. The company plans to expand its portfolio with digital pathology biomarkers and preclinical image analysis tools.Business & FinancialTechcyte, Pramana, And Aiosyn Collaborate To Advance Digital Pathology Workflow With Edge AI TechnologyTechcyte, Pramana, and Aiosyn announced a collaboration to integrate AI-powered breast and kidney histopathology analysis into digital pathology workflows. The integration uses Pramana's Edge AI and Aiosyn's IVDR-certified algorithms, with results displayed via DICOM annotations in Techcyte's Fusion platform.YahooAiosyn Mitosis Breast Becomes the First AI-Powered Mitosis Detection Solution to Achieve CE Mark Certification Under IVDRAiosyn announced its AI-powered mitosis counting algorithm achieved CE marking under the IVDR for breast cancer diagnostics. A multi-center study showed up to 60% time savings per slide, 15% productivity increase, and 32.6% consistency improvement. The company plans integrations with existing digital pathology software.Medical Device NetworkAiosyn and partners receive funding for cancer diagnostics developmentAiosyn, Radboud University medical centre and Pathologie-DNA have received a €1.3m ($1.4m) EFRO-OOST grant under the AIRAT project to develop AI tools for breast and skin cancer diagnostics. The partners will create CE-marked deep learning algorithms for automated mitosis detection, with Aiosyn handling algorithm development and validation and integration into digital pathology workflows such as Sectra.Business Wire BlogAiosyn’s AI-powered Quality Control for Digital Pathology Slides Is Now Available in Sectra Amplifier MarketplaceAiosyn announced its AI-powered quality control algorithm for digital pathology slides is now available in the Sectra Amplifier Marketplace. The software automatically flags common artifacts in histology slide images, reducing manual QC time. It is offered as a modular service for EU and UK laboratories.Business Wire BlogAiosyn Launches AI-powered Automated Quality Control to Improve the Digital Pathology WorkflowAiosyn launched AiosynQC, an AI-powered automated quality control tool for digital pathology labs. The algorithm scans H&E stained slides for common artifacts, flagging cases before pathologist review to improve workflow efficiency. The product is available as a modular service in the EU and UK, with more algorithms in development.EgirisimSağlık teknolojileri geliştiren Aiosyn, 2 milyon euro yatırım aldıDutch health-tech startup Aiosyn has secured 2 million euros in funding from Health Innovations, Oost NL, and LUMO Labs. The company develops AI-based algorithms to assist pathologists in improving diagnostic accuracy and workflow efficiency. With this capital, Aiosyn plans to accelerate its product development and expedite market entry.AiosynAiosyn HomepageAiosyn is introducing an AI-powered tool called Aiosyn Mitosis Breast that uses deep learning to detect cell division in whole slide images for breast cancer grading. The company specializes in developing AI pathology algorithms for cancer and kidney disease diagnosis, aiming to enhance workflow efficiency and diagnostic accuracy through cloud-based or on-premise deployment.AiosynAiosyn was awarded a NWO Take-off Phase 2 projectAiosyn, a Dutch AI pathology company, received Eur 250,000 in early-phase funding from NWO. The funds will support developing its quality management system and integrating its lead algorithm into clinical practice. The company aims to increase AI adoption in pathology diagnostics and improve cancer patient outcomes.